Back to News
Market Impact: 0.2
InflaRx N.V. Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Source: Nasdaq
Healthcare & Biotech
InflaRx announced that new preclinical data on izicopan in renal disease models will be presented at the American Society of Nephrology’s Kidney Week 2026. The company said in vivo and in vitro data showed robust inhibition of C5aR-mediated inflammatory responses; the available article text provides no clinical results or further figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
IFRX0.45
More News
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Palmer Luckey teams with dire wolf billionaire Ben Lamm to launch $200 million Warhound, unleashing genetically engineered clone dogs of war
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Zai Lab raises $250 million in private placement financing
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide